Announcement on Obtaining the “Approval Letter for Drug Clinical Trial” of an Innovative Drug
December 17, 2025
Source: drugdu
29
Securities Daily Online News: On the evening of December 16, Haisco Pharmaceutical Group issued an announcement stating that its subsidiary, Shanghai Haisco Shennuo Pharmaceutical Technology Co., Ltd., recently received the "Approval Letter for Drug Clinical Trial" issued by the National Medical Products Administration (NMPA). Following review, the Clinical Trial Applications (CTA) for HSK45019 Tablets, HSK50042 Tablets, HSK55718 for Injection, and HSK36357 Capsules, which were accepted in October 2025, have met the relevant requirements for drug registration. Approval has been granted to proceed with clinical trials.
https://finance.eastmoney.com/a/202512163593304242.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Subsidiary Signs Exclusive Licensing Agreement for GenSci098 Injection Project December 17, 2025
- Kangfeng Biotechnology’s Anti-Gastroesophageal Reflux System Receives Approval from the Drug Administration December 17, 2025
- Cell Metabolism | Efficacy of Akkermansia muciniphila Supplementation in Overweight/Obese Patients with Type 2 Diabetes December 17, 2025
- Major Breakthrough! China’s First Injectable Silk Fibroin Gel Enters Clinical Trials December 17, 2025
- Can AOC become the “next stop” for oligonucleotide therapy? December 17, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
